Please assess the completion status of the following clinical trial:

Trial Title: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.~* Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.~* Must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation.~Key Exclusion Criteria:~* No pigmented hair within any of the vitiligo areas on the face.~* Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).~* Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.~* Use of protocol-defined treatments within the indicated washout period before baseline.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
- Double-Blind Period: Vehicle cream BID (Type: PLACEBO_COMPARATOR): Participants applied matching vehicle cream BID for 24 weeks.
- Treatment-Extension Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
- Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).